TheraRadar
Clinical-Stage Companies / Taiho Pharmaceutical

Taiho Pharmaceutical

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 1/17/2023

27
Total Trials
5
Phase 3
12
Phase 2
5
Recruiting
204
Score

Pipeline by Phase

Phase 3
5
Phase 2
12
Phase 1
11

Therapeutic Focus

Colorectal Cancer Duchenne Muscular Dystrophy Stress Urinary Incontinence Gastric Cancer Head and Neck Cancer

Clinical Trials (27)

NCT04587908 Phase 3 ACTIVE NOT RECRUITING

A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy(REACH-DMD)

Started: 11/1/2020

NCT02322593 Phase 3 COMPLETED

Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

Started: 12/1/2014

NCT01955837 Phase 3 COMPLETED

Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia

Started: 9/1/2013

NCT01465464 Phase 3 TERMINATED

Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

Started: 12/1/2010

NCT00770874 Phase 3 COMPLETED

Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer

Started: 9/1/2008

NCT03175029 Phase 2 COMPLETED

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

Started: 9/9/2017

NCT02906683 Phase 2 COMPLETED

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

Started: 10/20/2016

NCT05335499 Phase 2 COMPLETED

A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

Started: 6/28/2022

NCT04512053 Phase 2 COMPLETED

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Started: 9/4/2020

NCT03605251 Phase 2 COMPLETED

Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.

Started: 8/30/2018

NCT02752048 Phase 2 COMPLETED

A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy

Started: 5/1/2016

NCT00721916 Phase 2 COMPLETED

Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer

Started: 7/1/2008

NCT00737360 Phase 2 TERMINATED

Phase II Study of TAS-106 to Treat Head and Neck Cancer

Started: 8/1/2008

NCT00824161 Phase 2 TERMINATED

Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

Started: 1/1/2009

NCT00661167 Phase 2 COMPLETED

Phase II Study of ABI-007 for Gastric Cancer

Started: 4/1/2008

NCT00891332 Phase 2 COMPLETED

Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer

Started: 10/1/2008

NCT04683250 Phase 1 RECRUITING

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Started: 12/16/2020

NCT04608110 Phase 1 RECRUITING

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Started: 10/30/2020

NCT04999761 Phase 1 RECRUITING

AB122 Platform Study

Started: 6/1/2021

NCT05245968 Phase 1 ACTIVE NOT RECRUITING

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Started: 12/1/2021

NCT02261532 Phase 1 COMPLETED

A Phase I Study of TAS-102 in Solid Tumors

Started: 9/1/2014

NCT05691660 Phase 1 COMPLETED

A Study of TAS3731 in Healthy Adults

Started: 1/17/2023

NCT05621447 Phase 1 COMPLETED

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Started: 9/7/2022

NCT04825431 Phase 1 COMPLETED

Mass Balance Study of [14C] TAS-205 in Healthy Volunteers

Started: 3/22/2021

NCT02246478 Phase 1 COMPLETED

A Study of TAS-205 for Duchenne Muscular Dystrophy

Started: 9/1/2014

NCT01610479 Phase 1 COMPLETED

A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors

Started: 6/1/2012

NCT02562807 Phase 1 COMPLETED

A Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Started: 10/1/2015

Drug Candidates

TAS0953/HM06 Pimitespib Imatinib Sunitinib ASTX030 TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort] Placebo [Ambulatory Cohort] only TAC-302 Placebo TAS-102
Activity Status: Stale
Last Trial Started: 1/17/2023
Last Trial Ended: 5/21/2024
Trials (12 months): 0
Completed Trials: 19
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.